Xvivo Perfusion AB (FRA:3XV) Cyclically Adjusted Revenue per Share: €1.35 (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:3XV Xvivo Perfusion AB FRA:3XV
85 GF Score
Price €21.10
GF Value €35.14
Valuation Significantly Undervalued
! 2 Warning Signs
View Full Analysis

What is Xvivo Perfusion AB Cyclically Adjusted Revenue per Share?

Xvivo Perfusion AB FRA:3XV -0.47% 85 Cyclically Adjusted Revenue per Share is €1.35 as of Jun. 2026. GuruFocus rates FRA:3XV with a GF Score™ of 85/100 and a GF Value™ of €35.14 (Significantly Undervalued). The stock has 2 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

Xvivo Perfusion AB's adjusted revenue per share for the three months ended in Jun. 2026 was €0.692. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is €1.35 for the trailing ten years ended in Jun. 2026.

During the past 12 months, Xvivo Perfusion AB's average Cyclically Adjusted Revenue Growth Rate was 15.90% per year. During the past 3 years, the average Cyclically Adjusted Revenue Growth Rate was 19.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of Xvivo Perfusion AB was 19.90% per year. The lowest was 19.90% per year. And the median was 19.90% per year.

As of today (2026-07-28), Xvivo Perfusion AB's current stock price is €21.10. Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share for the quarter that ended in Jun. 2026 was €1.35. Xvivo Perfusion AB's Cyclically Adjusted PS Ratio of today is 15.63.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xvivo Perfusion AB was 48.21. The lowest was 12.05. And the median was 27.31.


Xvivo Perfusion AB  (FRA:3XV) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

Xvivo Perfusion AB's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=21.10/1.35
=15.63

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of Xvivo Perfusion AB was 48.21. The lowest was 12.05. And the median was 27.31.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Related Terms


Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Historical Data

* Premium members only.

The historical data trend for Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Chart

Xvivo Perfusion AB Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.74 0.90 1.06 1.29

Xvivo Perfusion AB Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.22 1.23 1.29 1.27 1.35

FRA:3XV vs ABT, SYK, MDT: Cyclically Adjusted Revenue per Share Comparison

For the Medical Devices subindustry, Xvivo Perfusion AB's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Xvivo Perfusion AB Cyclically Adjusted PS Ratio vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Xvivo Perfusion AB's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where Xvivo Perfusion AB's Cyclically Adjusted PS Ratio falls into.


FRA:3XV
85GF Score
Xvivo Perfusion AB FRA:3XV
Cyclically Adjusted Revenue per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Xvivo Perfusion AB Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, Xvivo Perfusion AB's adjusted Revenue per Share data for the three months ended in Jun. 2026 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=0.692/134.1100*134.1100
=0.692

Current CPI (Jun. 2026) = 134.1100.

Xvivo Perfusion AB Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201609 0.139 101.138 0.184
201612 0.170 102.022 0.223
201703 0.165 102.022 0.217
201706 0.145 102.752 0.189
201709 0.128 103.279 0.166
201712 0.159 103.793 0.205
201803 0.160 103.962 0.206
201806 0.170 104.875 0.217
201809 0.146 105.679 0.185
201812 0.215 105.912 0.272
201903 0.170 105.886 0.215
201906 0.198 106.742 0.249
201909 0.189 107.214 0.236
201912 0.223 107.766 0.278
202003 0.161 106.563 0.203
202006 0.109 107.498 0.136
202009 0.141 107.635 0.176
202012 0.206 108.296 0.255
202103 0.195 108.360 0.241
202106 0.201 108.928 0.247
202109 0.186 110.338 0.226
202112 0.286 112.486 0.341
202203 0.294 114.825 0.343
202206 0.301 118.384 0.341
202209 0.304 122.296 0.333
202212 0.404 126.365 0.429
202303 0.420 127.042 0.443
202306 0.443 129.407 0.459
202309 0.411 130.224 0.423
202312 0.442 131.912 0.449
202403 0.522 132.205 0.530
202406 0.589 132.716 0.595
202409 0.552 132.304 0.560
202412 0.625 132.987 0.630
202503 0.630 132.825 0.636
202506 0.513 133.699 0.515
202509 0.545 133.480 0.548
202512 0.659 133.390 0.663
202603 0.709 133.560 0.712
202606 0.692 134.110 0.692

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.

What does a Cyclically Adjusted Revenue per Share of €1.35 mean?
Xvivo Perfusion AB (FRA:3XV) has a Cyclically Adjusted Revenue per Share of €1.35 as of Jun. 2026. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors.
Is Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share too high?
Xvivo Perfusion AB's current Cyclically Adjusted Revenue per Share is €1.35. Overall, Xvivo Perfusion AB has a GF Score™ of 85/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share compare to ABT and SYK?
Xvivo Perfusion AB's Cyclically Adjusted Revenue per Share of €1.35 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Revenue per Share for a Medical Devices & Instruments company?
A good Cyclically Adjusted Revenue per Share depends on the Medical Devices & Instruments industry context. However, Cyclically Adjusted Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Revenue per Share mean?
A high Cyclically Adjusted Revenue per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted revenue per share represents the company's inflation-adjusted revenue per share over a 10-year period. View historical data on Xvivo Perfusion AB and its competitors. Xvivo Perfusion AB's current Cyclically Adjusted Revenue per Share is €1.35. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Xvivo Perfusion AB stock overvalued right now?
Based on GuruFocus' analysis, Xvivo Perfusion AB (FRA:3XV) is currently considered Significantly Undervalued. The stock's GF Value™ is €35.14, compared to a current price of €21.10 — trading 40% below its estimated fair value. The current Cyclically Adjusted Revenue per Share is €1.35. Xvivo Perfusion AB's overall GF Score™ is 85/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Revenue per Share calculated?
Cyclically Adjusted Revenue per Share is calculated from a company's financial statements. For Xvivo Perfusion AB (FRA:3XV), the current Cyclically Adjusted Revenue per Share is €1.35 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Xvivo Perfusion AB (FRA:3XV) Overvalued in 2026?

Based on GuruFocus' analysis, Xvivo Perfusion AB stock appears to be undervalued. The current stock price of €21.10 is trading 40% below its estimated GF Value™ of €35.14. GuruFocus considers Xvivo Perfusion AB to be Significantly Undervalued.

Key valuation signals for FRA:3XV:

  • Cyclically Adjusted Revenue per Share: €1.35
  • GF Value™: €35.14 vs. price of €21.10 (40% below fair value)
  • GF Score™: 85/100 with 2 warning signs

No single metric tells the full story. See the FRA:3XV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Xvivo Perfusion AB Business Description

Address Gemenskapens gata 9, Molndal, SWE, SE-431 53
Xvivo Perfusion AB is a medical technology company dedicated to extending the life of organs so transplant teams around the world can save more lives. Its solutions allow clinicians and researchers to push the boundaries of transplantation medicine. It operates in three segments, namely Thoracic: sales of lung and heart transplant products; Abdominal: sales of liver and kidney transplant products and perfusion services; and Services: revenue from the sale of services related to organ recovery, as well as digital products for communication and workflow management at transplantation clinics. The majority of revenue is derived from the Thoracic segment, and geographically, the majority is from the United States.
85GF Score

Get the complete analysis for FRA:3XV

Cyclically Adjusted Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€21.10
Price
€35.14
GF Value